FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE [PDF]
Revista do Instituto de Medicina Tropical de São Paulo, 2014 Introduction: Pentavalent antimonials are the first drug of choice in the treatment of tegumentary leishmaniasis. Data on ototoxicity related with such drugs is scarcely available in literature, leading us to develop a study on cochleovestibular ...
Cláudia Maria Valete-Rosalino +12 more
doaj +6 more sources
Novel methods for the encapsulation of meglumine antimoniate into liposomes [PDF]
Brazilian Journal of Medical and Biological Research, 2000 The antimonial drug, meglumine antimoniate, was successfully encapsulated in dehydration-rehydration vesicles and in freeze-dried empty liposomes (FDELs).
F. Frézard +3 more
doaj +6 more sources
Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis [PDF]
Revista da Sociedade Brasileira de Medicina Tropical, 2016 INTRODUCTION: Intralesional treatment for cutaneous leishmaniasis has been applied for over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results and without relevant systemic toxicity. METHODS Meglumine antimoniate was
Maria Cristina de Oliveira Duque +7 more
doaj +4 more sources
Revista da Sociedade Brasileira de Medicina Tropical, 2019 Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine antimoniate administration has fewer adverse effects and can be as effective and ...
Margarita Arboleda +3 more
doaj +3 more sources
Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis [PDF]
Dermatology Research and Practice, 2011 The purpose of this study was to investigate comparison between oral zinc sulfate and meglumine antimoniate in the treatment of cutaneous leishmaniasis (CL). So 100 patients with CL were included and randomly divided into two groups.
Mohamad Javad Yazdanpanah +6 more
doaj +2 more sources
Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate [PDF]
Open Access Macedonian Journal of Medical Sciences, 2017 Hoigne syndrome (HS) is the term coined to describe an acute, non-allergic, psychiatrically based reaction occurring with a wide list of medications, mainly antibiotics. Since its first description by Hoigne and Schoch in 1959, few cases have been reported in medical literature and, although antimicrobials are commonly used, very rarely in dermatology.
Guarneri, Claudio +3 more
openaire +5 more sources
Embryonic toxico-pathological effects of meglumine antimoniate using a chick embryo model. [PDF]
PLoS ONE, 2018 Leishmaniasis is one of the diverse and neglected tropical diseases. Embryo-toxicity of drugs has always been a major concern. Chick embryo is a preclinical model relevant in the assessment of adverse effects of drugs.
Ahmad Khosravi +7 more
doaj +2 more sources
Revista da Sociedade Brasileira de Medicina TropicalAlthough New World cutaneous leishmaniasis is not itself a life-threatening disease, its treatment with systemic antimonials can cause toxicity that can be dangerous to some patients.
Maria Inês Fernandes Pimentel +7 more
doaj +2 more sources
American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report [PDF]
Revista da Sociedade Brasileira de Medicina Tropical, 2011 This is a case report of a Brazilian soldier with cutaneous leishmaniasis. The lesion relapsed following two systemic treatments with meglumine antimoniate.
Maria Inês Fernandes Pimentel +11 more
doaj +2 more sources
Speciation of antimony (III) and antimony (V) using hydride generation for meglumine antimoniate pharmaceutical formulationsquality control [PDF]
Memorias do Instituto Oswaldo Cruz, 2008 The pentavalent antimonies, mainly the meglumine antimoniate, are recommends as first-choice medicines for leishmaniasis therapy. In this work we described the development of formulations of meglumine antimoniate injectable medication, as well as the ...
Lúcio Mendes Cabral +7 more
doaj +4 more sources